Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Prostatic Neoplasms 2Pancreatic Neoplasms 2Hypoxia 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 15pembrolizumab 13Doxorubicin 13Radiotherapy 12Docetaxel 9Nivolumab 8Filgrastim 7Cyclophosphamide 7pazopanib 6Ifosfamide 6130-nm albumin-bound paclitaxel 5Temozolomide 4Irinotecan 4Ipilimumab 4Imatinib Mesylate 4Albumin-Bound Paclitaxel 4talimogene laherparepvec 3surufatinib 3pegfilgrastim 3eribulin 3atezolizumab 3Vinorelbine 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3PM 01183 3Drug Therapy 3Cisplatin 3toripalimab 2spartalizumab 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma × TH 302 × Clear all
NCT00742963 2025-05-13

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

ImmunoGenesis

Phase 1/2 Completed
107 enrolled 7 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡